Chemokine Receptor-5Δ32 Mutation is No Risk Factor for Ischemic-Type Biliary Lesion in Liver Transplantation

Table 1

Recipient characteristics. MELD: model for end-stage liver disease; CPS: Child-Pugh score; BG: recipients blood group; wt/wt: wild-type CCR-5; wt/Δ32: heterozygous CCR-5Δ32; Δ32/Δ32: homozygous CCR-5Δ32; CMV: cytomegalovirus; OKT-3: monoclonal murine anti-CD-3 antibody.

Recipient characteristics
Variables	wt/wt	wt/Δ32	Δ32/Δ32	P-value
n (169)	134 (79.3%)	33 (19.5%)	2 (1.2%)
Recipient gender
Male	89 (66.4%)	22 (66.7%)	—	.137
Female	45 (33.6%)	11 (33.3%)	2 (100%)
Mean recipient age (years)	50.2±10.3	49.8±9.9	47.5±17.7	.443
MELD Score (mean ± SD)	17.2±8.7	17.9 ± 9	—	.960
CPS A	13 (11.8%)	4 (16%)	1 (50%)	.487
CPS B	60 (54.5%)	13 (52%)	1 (50%)
CPS C	37 (33.7%)	8 (32%)	—
BG A	52 (39.1%)	10 (30.3%)	1 (50%)	.823
BG B	19 (14.3%)	4 (12.1%)	—
BG AB	15 (11.3%)	3 (9.1%)	—
BG O	47 (35.3%)	16 (48.5%)	1 (50%)
Hepatitis B-related cirrhosis	16 (11.9%)	3 (9.1%)	—	.918
Hepatitis C-related cirrhosis	21 (15.7%)	6 (18.2%)	—
Hepatocellular carcinoma	19 (14.2%)	4 (12.1%)	—
Primary biliary cirrhosis	6 (4.5%)	—	2 (100%)
Primary sclerosing cholangitis	4 (3%)	2 (6.1%)	—
Acute liver failure	4 (3%)	3 (9.1%)	—
Autoimmune hepatitis	2 (1.5%)	—	—
Metabolic liver diseases	2 (1.5%)	3 (9.1%)	—
Alcohol-induced cirrhosis	41 (30.6%)	9 (27.3%)	—
Retransplantation	4 (3%)	1 (3%)	—
Others	15 (11.2%)	2 (6.1%)	—
Cold ischemic time (minutes)	533 ± 144	582 ± 202	633	.806
Initial Immunosuppression
Tacrolimus	110 (82.6%)	28 (84.8%)	2 (100%)	.824
Cyclosporine A	23 (17.2%)	4 (12.1%)	—
others	1 (0.7%)	1 (3.0%)	—
HLA match
0 match	24 (26.4%)	6 (27.3%)	2 (100%)	.448
1 match	40 (44.0%)	8 (36.4%)	—
2 matches	21 (23.1%)	5 (19.2%)	—
3 matches	5 (5.5%)	2 (9.1%)	—
4–6 matches	1 (1.1%)	1 (4.5%)	—
CMV Infection
postitve	43 (32.1%)	12 (36.4%)	2 (100%)	.117
negative	28 (20.9%)	2 (6.1%)	—
unknown	63 (47.0%)	19 (57.6%)	—